Survival rates are lower for patients with high-risk melanoma with mutations
the ONA take:
Researchers from UNC Lineberger Comprehensive Cancer Center analyzed melanoma samples to determine if tumors with the BRAF or NRAS gene mutations indicated poorer prognosis for those patients.
This study was conducted before new treatments for melanoma were approved, including the first BRAF inhibitor approved in 2011. Therefore, the connection between the mutations and outcomes were determined without the influence of the new drugs.
In this study, 912 patients with melanoma were followed for 7 years. All the patients were enrolled through the GEM study, and their diagnoses were made in 2000.
Thirteen percent of patients had tumors with NRAS mutations, 30% had BRAF mutations, and 57% had neither mutation. The researchers found that 73% of patients with high-risk, NRAS-mutated tumors and 71% of patients with high-risk, BRAF-mutated tumors survived 5 years, compared with 82% of high-risk tumors with neither mutation.
Overall, no statistical difference was seen in 5-year survival for people with NRAS or BRAF mutations compared with those people who had no mutation.
However, 5-year survival was lower in people with high-risk tumors with mutations.
No statistical difference was seen in 5-year survival for melanoma patients with NRAS or BRAF mutations.
- Study Identifies Factors Associated With Hearing Loss in Polycythemia Vera
- High Symptom Burden With Polycythemia Vera Linked to QoL Impairment
- Bioimpedence Spectroscopy Improves Early Detection of Breast Cancer-Related Lymphedema in At-Risk Patients
- Ezh2 Inhibitors May Offer Cure for Chronic Myelogenous Leukemia
- Ruxolitinib: A Targeted Treatment Option for Patients with Polycythemia Vera
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Tumor Markers (Fact Sheet)
- Implementing a Distress Screening Process for Cancer Patients
- ASCO, ASTRO Issue Guideline Update for Postmastectomy RT
- Study Assesses Efficacy of Ramucirumab in HCC by Child-Pugh Score
- Incontinence Affects QOL for Survivors of Gynecologic Cancers
- Patient Navigation Reduces Delays in Diagnostic Resolution
- Fee-for-service Medicare Plans Linked to Improved Care During Last Year of Life
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|